Santos C, et al. – A research was formulated with the goal to evaluate the added predictive value of an extended RAS panel testing using two commercial assays and a highly sensitive and quantitative digital PCR (dPCR). RAS and BRAF mutational analysis improved prediction of response to anti–EGFR therapy. However, the rate of mutations observed among techniques was different. dPCR with a threshold of 1% outperformed the other platforms.